Filing Details

Accession Number:
0000886163-18-000046
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-03-09 18:28:41
Reporting Period:
2018-03-08
Accepted Time:
2018-03-09 18:28:41
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
886163 Ligand Pharmaceuticals Inc LGND Pharmaceutical Preparations (2834) 770160744
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1376960 Jason Aryeh 3911 Sorrento Valley Boulevard, Ste 110
San Diego CA 92121
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2018-03-08 3,500 $174.88 83,334 No 4 S Indirect Indirect
Common Stock Disposition 2018-03-09 4,000 $176.47 79,334 No 4 S Indirect Indirect
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect Indirect
No 4 S Indirect Indirect
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 58,625 Direct
Common Stock 5,025 Indirect by Trust
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $174.49 to $175.24, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  2. All securities disclosed in this Form 4 are owned by certain funds managed by JALAA Equities, LP, JLV Investments, LP and affiliates (the "Funds"). Jason Aryeh is the General Partner of JALAA Equities, LP and a partner of JLV Investments, LP. By reason of the provisions of Rule 16a-1 under the Securities Exchange Act of 1934, as amended, JALAA Equities, LP, JLV Investments, LP and affiliates and Mr. Aryeh may be deemed to be the beneficial owners of the securities beneficially owned by the Funds.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $175.99 to $177.49, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.